Jindriska Lindsay, Alina Striha, Roger G. Owen, John R Jones, David Allotey, S. Shafeek, Faith E. Davies, Graham Jackson, David A Cairns, Graham P. Cook, Martin Kaiser, W Gregory, Gareth J. Morgan, Claire Chapman, Mark T. Drayson, Anna Chalmers, Kamaraj Karunanithi, Charlotte Pawlyn, Nigel H. Russell, Donald Milligan, and Corinne Collett
e50 (56.1 vs 29.2 vs 39.9 months, p1⁄40.005) (Figure 1). The estimated overall survival (OS) at 8 years was 60% with no significant differences among the 3 arms. In the overall series, the PFS was significantly shorter in patients with high-risk cytogenetics compared with patients with standard-risk (15.7 months vs. 44.3 months, p1⁄40.003). In the TD and in the VBMCP/VBAD/B arm patients with high-risk cytogenetics had a significantly shorter PFS than patients with standard-risk (8.9 vs 32.8 months, p1⁄40.04 in TD group; 14.1 vs. 43.3 months, p1⁄40.05 in VBMVP/VBAD/B group). However, there was no significantly difference in the VTD arm (23.6 vs 56.1 months, p1⁄40.2). Patients with high-risk cytogenetics had a significantly shorter OS in the overall series (median 42.1 months vs not reached, p1⁄40.00001) and this was observed in the three treatment arms: VTD median 37.1 months vs not reached (p1⁄40.001); TD median 54.2 months vs not reached (p1⁄40.06); VBMCP/VBAD/B median 30.2 months vs not reached, p1⁄40.007). Conclusions: The PFS of 56 months achieved with VTD is the longest ever reported in the first line treatment of patients with MM elegible for ASCT.